Longitudinal Assessment of Circulating Tumor Cells Expressing PD-L1 and Clusters in Esophageal Cancer Patients

A longitudinal study of 110 esophageal cancer patients evaluated CTCs, PD-L1 expression, and CTC clusters, highlighting their potential as predictive biomarkers for treatment outcomes and occult minimal cellular residual disease.

Detection of Androgen Receptor Splice Variant 7 in Circulating Tumor Cells for Dynamic Treatment Decision in Prostate Cancer Patients

This study evaluated AR-V7 in CTCs and clusters from prostate cancer patients, highlighting its potential to predict ARSI resistance and support dynamic treatment decisions.

Algorithm based analysis of circulating tumour cells in cancer patients

A study evaluating CellMatrics, a Python-based automated image analysis algorithm for CTC detection, demonstrated rapid and robust concordance with manual CTC analysis across blood samples from 32 cancer patients.

Assessment of apprehension for Minimal Cellular Residual Disease Using Circulating Tumour Cells in Pre and Post Surgery Breast Cancer Patients

A prospective study evaluates RUPIKA, a structured CTC-based MRD disclosure protocol, showing significantly reduced cancer worry among breast cancer patients after surgery compared with routine result communication.

Capture of Epithelial-Mesenchymal Transitioning Circulating Tumor Cells using Affinity Based N-Cadherin System

A study demonstrating N-Cadherin affinity-based capture of EMT-associated CTCs in diverse cancers, with Vimentin-positive CTC detection in 90% of samples and N-Cadherin expression revealing heterogeneous metastatic phenotypes.

Capture of Cancerous Cells and Overall Survival in Rats using Ex-vivo Extracorporeal Device in Multiple Onco-dialysis Cycles

An animal study evaluated OncoMetastat for ex-vivo cancer cell capture, safety, and survival in rats. Across multiple onco-dialysis cycles, cancer cells were captured, all test-group rats survived 14 days, and histopathology showed normal tissues.

Comparative Analysis of Circulating Tumor Cells, Clusters, and PD-L1 Expression in Paired
Peripheral and Portal Venous Blood with Solid Malignancies

A prospective study compares circulating tumor cells, CTC clusters, and PD-L1 expression in paired peripheral and portal venous blood, highlighting compartment-specific differences and the potential of dual-compartment liquid biopsy profiling.

Evaluation of circulating tumor cells expressing PD-L1 and CTC clusters at baseline and follow ups in triple-negative breast cancer

A retrospective study of 180 TNBC blood samples evaluated CTC burden, PD-L1 expression and CTC clusters using the CDSCO-approved OncoDiscover platform, highlighting their potential for longitudinal disease monitoring and biomarker-guided management.

ASCO 2026 : Association of circulating tumor cells with PD-L1 expression and clusters in confirmative tumor thrombus in selective solid cancers.

Study shows circulating tumor cells with PD-L1 expression in tumor thrombus patients, indicating active dissemination and potential metastatic risk.

ASCO 26: Assessment of circulating tumor cells and clusters expressing PD-L1 in urological cancers

High prevalence of PD-L1–positive circulating tumor cells in urological cancers, especially prostate cancer, indicating minimal residual disease and recurrence risk.

ASCO 2026: Comparative enumeration of circulating tumor cells with PD-L1 over expression using anti EpCAM antibody to N-Cadherin in solid cancers

Dual EpCAM and N-cadherin profiling improves circulating tumor cell detection, enhancing minimal residual disease surveillance and identifying metastasis-prone cells.

AACR 2026: Over expressing PD-L1 circulating tumor cells with clusters in prostate cancer patients

Study shows high prevalence of PD-L1–positive circulating tumor cells in prostate cancer, highlighting their value for monitoring disease progression and immune evasion.

ASCO 2026: Continual depletion of circulating tumor cells using an automated device enriched with affinity glass bead substrates in breast and CRC patient's whole blood.

Automated OncoMetastat device captures and depletes CTCs in colorectal and breast cancer, aiding detection of minimal residual disease and metastasis risk.

AACR 2026: Depletion of circulating tumor cells using an automated device using non-hemolytic affinity-based substrates

Actorius Innovations presents accepted research abstracts at the AACR Annual Meeting 2026, highlighting advances in cancer diagnostics, therapeutics and liquid biopsy.

AACR 2020: Clinical correlation of circulating tumor cells as a blood marker in Indian head and neck cancer patients.

A study of 350 Indian HNC patients confirms CTCs correlate with nodal stage and aggressive features, validating their use as a clinical staging marker.

PD-L1 over-expression on Circulating Tumor Cells in Endometrial Cancer Patients

Khandare J, Ghadyalpatil N, Raja T, Velukuru S, Jadhav V, Satape R, Shinde S, Ashturkar A, Dattatreya P, Vasudevan A

Actorius Innovations And Research, Pune, Maharashtra, India; Apollo Cancer Institute, Hyderabad, Telangana, India; Apollo Cancer Centre, Chennai, Tamil Nadu, India; Aster CMI Hospital, Bangaluru, Karnataka, India; Renova Soumya Cancer Center, Hyderabad, Telangana, India.

Assessment of PD-L1 Expression on Circulating Tumor Cells and Clusters in Gastric Cancer Patients

Circulating tumor cells with PD-L1 expression and clusters are common in gastric cancer, indicating minimal residual disease and recurrence risk.

Automated Continual Flow Device to Deplete Circulating Tumor Cells using Spiral Cartridge Mediated by Antibody and Transferrin Glass Substrate

Automated OncoMetastat device captures and depletes circulating tumor cells from whole blood safely, supporting extracorporeal cancer therapy and monitoring.

Association of Circulating Tumor Cell Dynamics with Patient-Reported Cancer Worry in Post-Surgical Breast Cancer Patients

Circulating tumor cell monitoring before and after breast cancer surgery reveals minimal residual disease and correlates with post-surgical cancer worry.

Circulating Biomarkers Reveal their Complementary Association in Primary and Metastatic Colorectal Cancer Patients

Combined CTC and ctDNA analysis reveals strong prognostic value for monitoring progression and metastasis in colorectal cancer patients.